First published online
April 16, 2009, 10.2967/jnumed.108.055533
Microbial Targeting of 99mTc-Labeled Recombinant Human β-Defensin-3 in an Animal Model of Infection: A Feasibility Pilot Study
Mauro Liberatore1,
Alessandro Pala2,
Sergio Scaccianoce3,
Christos Anagnostou1,
Ugo Di Tondo4,
Enrico Calandri1,
Piera D'Elia2,
Milton D. Gross5 and
Domenico Rubello6
1 Nuclear Medicine Unit, Department of Radiological Sciences, "La Sapienza" Rome University, Rome, Italy; 2 Perinatology and Puericulture Unit, Laboratory of Biochemistry of Sex Hormones, Department of Gynaecological Sciences, "La Sapienza" Rome University, Rome, Italy; 3 Department of Human Physiology and Pharmacology, "La Sapienza" Rome University, Rome, Italy; 4 Department of Experimental Medicine and Pathology, "La Sapienza" Rome University, Rome, Italy; 5 Nuclear Medicine Service, Department of Veteran Affairs Health System, Ann Arbor, Michigan; and 6 Department of Nuclear Medicine, "S. Maria della Misericordia" Hospital, Rovigo, Italy

View larger version (80K):
[in this window]
[in a new window]
|
FIGURE 1. Sites of tissue sampling and relative histologic findings (hematoxylin–eosin staining): normal muscle (A), S. aureus–induced infection (B), and carrageenan-induced inflammation (C). Extensive infiltration of leukocytes can be seen in B and C, whereas presence of bacteria was demonstrated in infection site only (B) by cultural examination and Gram staining of relative sample.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
FIGURE 2. Dose-dependent uptake of 99mTc-labeled HBD-3 by infection (A) and sterile inflammation (B) sites. Normal muscle (C) was used as control. Nor. = normal.
|
|
Copyright © 2009 by the Society of Nuclear Medicine.